Phase 3 Hepatocellular Carcinoma Non-resectable Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University178 enrolled1 locationNCT06492395
Recruiting
Phase 3
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University258 enrolled1 locationNCT05985798
Recruiting
Phase 3
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University427 enrolled1 locationNCT05608200
Recruiting
Phase 3
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University187 enrolled1 locationNCT05608213